Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer
Gynaecological Cancers
Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer
Durvalumab addition to chemo shows endometrial cancer benefit
Part 6: Which different PARP inhibitors are available
Part 7: Similarities and Differences
Part 8: How PARP inhibitors are being used now
Part 9: What PARP inhibitors mean for the future and what to look out for
The case for investing in women's cancers in Asia Pacific
Nigeria solidarity support fund and the annual youth engagement campaign on HPV